DEVONIAN HEALTH GROUP INC (GSD.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:GSD - CA2518348008 - Common Stock
0.22 CAD
-0.03 (-12%)
GSD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 32 industry peers in the Pharmaceuticals industry. GSD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GSD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
GSD had negative earnings in the past year.
In the past year GSD had a positive cash flow from operations.
GSD had negative earnings in each of the past 5 years.
GSD had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
GSD has a Return On Assets of -22.47%. This is in the lower half of the industry: GSD underperforms 68.75% of its industry peers.
GSD has a worse Return On Equity (-58.41%) than 65.63% of its industry peers.
GSD has a Return On Invested Capital of 8.78%. This is amongst the best in the industry. GSD outperforms 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.47% | ||
| ROE | -58.41% | ||
| ROIC | 8.78% |
ROA(3y)-15.3%
ROA(5y)-19%
ROE(3y)-22.22%
ROE(5y)-31.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 3.30%, GSD is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
With a Gross Margin value of 37.10%, GSD perfoms like the industry average, outperforming 53.13% of the companies in the same industry.
GSD's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.3% | ||
| PM (TTM) | N/A | ||
| GM | 37.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-5.88%
2. Health
2.1 Basic Checks
GSD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for GSD has been increased compared to 1 year ago.
The number of shares outstanding for GSD has been increased compared to 5 years ago.
The debt/assets ratio for GSD has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.43, we must say that GSD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.43, GSD is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
The Debt to FCF ratio of GSD is 0.02, which is an excellent value as it means it would take GSD, only 0.02 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.02, GSD belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that GSD is not too dependend on debt financing.
GSD has a better Debt to Equity ratio (0.01) than 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.02 | ||
| Altman-Z | 1.43 |
ROIC/WACC1.09
WACC8.06%
2.3 Liquidity
GSD has a Current Ratio of 1.12. This is a normal value and indicates that GSD is financially healthy and should not expect problems in meeting its short term obligations.
GSD has a Current ratio of 1.12. This is in the lower half of the industry: GSD underperforms 78.13% of its industry peers.
GSD has a Quick Ratio of 1.12. This is a normal value and indicates that GSD is financially healthy and should not expect problems in meeting its short term obligations.
GSD has a Quick ratio of 1.12. This is comparable to the rest of the industry: GSD outperforms 46.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The earnings per share for GSD have decreased strongly by -60.37% in the last year.
GSD shows a strong growth in Revenue. In the last year, the Revenue has grown by 237.82%.
Measured over the past years, GSD shows a very strong growth in Revenue. The Revenue has been growing by 26.59% on average per year.
EPS 1Y (TTM)-60.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1146.15%
Revenue 1Y (TTM)237.82%
Revenue growth 3Y135.68%
Revenue growth 5Y26.59%
Sales Q2Q%43.66%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GSD. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
GSD's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GSD indicates a rather cheap valuation: GSD is cheaper than 93.75% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.34 | ||
| EV/EBITDA | 15.74 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for GSD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:GSD (12/2/2025, 7:00:00 PM)
0.22
-0.03 (-12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.65%
Ins Owner ChangeN/A
Market Cap36.51M
Revenue(TTM)32.94M
Net Income(TTM)-5.16M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.11 | ||
| P/FCF | 4.34 | ||
| P/OCF | 4.33 | ||
| P/B | 4.13 | ||
| P/tB | 9.29 | ||
| EV/EBITDA | 15.74 |
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.05
FCFY23.05%
OCF(TTM)0.05
OCFY23.11%
SpS0.2
BVpS0.05
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.47% | ||
| ROE | -58.41% | ||
| ROCE | 12.19% | ||
| ROIC | 8.78% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 3.3% | ||
| PM (TTM) | N/A | ||
| GM | 37.1% | ||
| FCFM | 25.54% |
ROA(3y)-15.3%
ROA(5y)-19%
ROE(3y)-22.22%
ROE(5y)-31.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-5.88%
F-Score6
Asset Turnover1.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.02 | ||
| Debt/EBITDA | 0.05 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 493.88% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 1.43 |
F-Score6
WACC8.06%
ROIC/WACC1.09
Cap/Depr(3y)3.28%
Cap/Depr(5y)2.81%
Cap/Sales(3y)1.16%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1146.15%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)237.82%
Revenue growth 3Y135.68%
Revenue growth 5Y26.59%
Sales Q2Q%43.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y137.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y296.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y297.04%
OCF growth 3YN/A
OCF growth 5YN/A
DEVONIAN HEALTH GROUP INC / GSD.CA FAQ
What is the fundamental rating for GSD stock?
ChartMill assigns a fundamental rating of 3 / 10 to GSD.CA.
What is the valuation status for GSD stock?
ChartMill assigns a valuation rating of 2 / 10 to DEVONIAN HEALTH GROUP INC (GSD.CA). This can be considered as Overvalued.
Can you provide the profitability details for DEVONIAN HEALTH GROUP INC?
DEVONIAN HEALTH GROUP INC (GSD.CA) has a profitability rating of 2 / 10.
How financially healthy is DEVONIAN HEALTH GROUP INC?
The financial health rating of DEVONIAN HEALTH GROUP INC (GSD.CA) is 5 / 10.